StreetInsider.com News Articles

Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'

Tue, 01 Sep 2026 06:32:01 -0400

(Updated - September 1, 2026 6:32 AM EDT)

Piper Sandler analyst David Westenberg upgraded Tempus AI Inc (NASDAQ: TEM) from Neutral to Overweight with a price target of $76.00.

The analyst comments "We are upgrading shares of TEM to Overweight from Neutral and raise our PT to $76 from $56. Our Neutral rating reflected a stock valuation that, in our view, was being driven more by AI sentiment and was not correlating with the performance of its diagnostics and data businesses. Three growth drivers that were previously difficult to underwrite are now increasingly visible: (1) the pending acquisition of Personalis gives Tempus

Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'

Tue, 01 Sep 2026 06:32:01 -0400

(Updated - September 1, 2026 6:32 AM EDT)

Piper Sandler analyst David Westenberg upgraded Tempus AI Inc (NASDAQ: TEM) from Neutral to Overweight with a price target of $76.00.

Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'

Tue, 01 Sep 2026 06:32:01 -0400

(Updated - September 1, 2026 6:32 AM EDT)

Piper Sandler analyst David Westenberg upgraded Tempus AI Inc (NASDAQ: TEM) from Neutral to Overweight with a price target of $76.00.

Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'

Tue, 01 Sep 2026 06:32:01 -0400

(Updated - September 1, 2026 6:32 AM EDT)

Piper Sandler analyst David Westenberg upgraded Tempus AI Inc (NASDAQ: TEM) from Neutral to Overweight with a price target of $76.00.

Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'

Tue, 01 Sep 2026 06:32:01 -0400

(Updated - September 1, 2026 6:32 AM EDT)

Piper Sandler analyst David Westenberg upgraded Tempus AI Inc (NASDAQ: TEM) from Neutral to Overweight with a price target of $76.00.

Canaccord Reiterates Buy Rating on Tempus AI Inc (TEM)

Tue, 01 Sep 2026 03:54:58 -0400

Canaccord analyst Kyle Mikson reiterated a Buy rating and $80.00 price target on Tempus AI Inc (NASDAQ: TEM).

The analyst comments "We reiterate our BUY rating and $80 PT. After the market close on 8/31, TEM filed its S-4 related to the pending acquisition of Personalis (PSNL). Notably, the filing outlines a competitive sale process that initially began in May 2024 and attracted interest from multiple strategic parties thereafter, including "Party A," a direct competitor whose proposal raised significant antitrust and regulatory concerns for the PSNL board. We view this broader strategic interest as further validation of the value of PSNL's

Form 4 Tempus AI, Inc. For: Aug 25 Filed by: LEFKOFSKY ERIC P

Thu, 27 Aug 2026 20:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991761.html

Form 4 Tempus AI, Inc. For: Aug 25 Filed by: LEFKOFSKY ERIC P

Thu, 27 Aug 2026 20:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991761.html

Form 4 Tempus AI, Inc. For: Aug 25 Filed by: LEFKOFSKY ERIC P

Thu, 27 Aug 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260827/26991760.html

Form 4 Tempus AI, Inc. For: Aug 25 Filed by: LEFKOFSKY ERIC P

Thu, 27 Aug 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260827/26991760.html

Form 144 Tempus AI, Inc. Filed by: LEFKOFSKY ERIC P

Tue, 25 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975518.html

Form 144 Tempus AI, Inc. Filed by: LEFKOFSKY ERIC P

Tue, 25 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975518.html

Form 4 Tempus AI, Inc. For: Aug 21 Filed by: Schoenherr Thomas Edward

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974933.html

Form 4 Tempus AI, Inc. For: Aug 21 Filed by: Schoenherr Thomas Edward

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974933.html

Form 4 Tempus AI, Inc. For: Aug 21 Filed by: Fukushima Ryan

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974938.html

Form 4 Tempus AI, Inc. For: Aug 21 Filed by: Fukushima Ryan

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974938.html

Tempus AI gets FDA clearance for ECG-based AI pulmonary hypertension tool

Mon, 24 Aug 2026 08:32:39 -0400

Tempus AI, Inc. (NASDAQ: TEM) has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension.

The clearance marks the third FDA-cleared cardiovascular device in Tempus' portfolio, joining previously cleared products for atrial fibrillation and low ejection fraction.

Tempus ECG-PH is designed to detect signs associated with elevated mean pulmonary artery pressure above 20 mmHg. It is intended for use on ECG recordings collected at healthcare facilities from patients 40 years of age or older who present with cardiovascular symptoms such as dyspnea, fatigue,

Tempus AI gets FDA clearance for ECG-based AI pulmonary hypertension tool

Mon, 24 Aug 2026 08:32:39 -0400

The clearance marks the third FDA-cleared cardiovascular device in Tempus' portfolio, joining previously cleared products for atrial fibrillation and low ejection fraction.

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Mon, 24 Aug 2026 08:30:00 -0400

ECG-PH clearance adds pulmonary hypertension to Tempus’ FDA-cleared AI products for atrial fibrillation and low ejection fraction

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at identifying patients at risk for complex cardiac conditions.